Innovus Pharmaceuticals Inc. plans to sell common stock and warrants in an underwritten public offering.

The company intends to use the net proceeds from the offering for the commercial launch of allergic rhinitis treatment FlutiCare, working capital and general corporate purposes, including sales and marketing activities, product development and capital expenditures.

H.C. Wainwright & Co. LLC is acting as the exclusive placement agent for the offering.